GSK-FAK114746

Study Sponsor: GSK

Study Title

A Phase 1b, multi-center, open-label, dose escalation study of GSK2256098 (FAK inhibitor) in combination with Trametinib (MEK inhibitor) in subjects with advanced solid tumors

Medicine or Vaccine (generic name)

GSK2256098; trametinib

Sponsor Identification Number

FAK114746

Trial Registry Identification Number(#'s)

NCT01938443 2013-000784-85

Medical Condition

Neoplasms

Phase

Phase 1

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=114746

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT01938443

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2013-000784-85

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

May 2019